Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

By W. De Roock, B. Claes, David Bernasconi, J. De Schutter, B. Biesmans, G. Fountzilas, K. Kalogeras, V. Kotoula, D. Papamichael, P. Laurent-Puig and 27 more. The Lancet Oncology, 2010

2,124 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/fd225c39db7e20768277da6b44ade77cf8405036

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Gad Getz
2. Matthew Meyerson
3. Kristian Cibulskis
4. M. Lawrence
5. Michael R. Stratton
6. A. Bardelli
7. Hans Clevers
8. Alexander van Oudenaarden

In Oncology

1. Hans Clevers
2. Alexander van Oudenaarden
3. Fortunato Ciardiello
4. Michael R. Stratton
5. Gad Getz
6. Pengfei Lu

In Pathology and Forensic Medicine

1. A. Bardelli
2. Hans Clevers

Citations in the corpus

• Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “RAS mutations and BRAF mutations are usually mutually exclusive [64].”
• Prospective derivation of a Living Organoid Biobank of colorectal cancer patients (2015, background): “Accession Numbers GSE64392 GSE65253”
• ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. (2012, background): “The prognostic value of KRAS mutations is not completely elucidated yet with conflicting results [27–30].”
• A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. (2011, background): “When considering the cumulative incidence of these genetic alterations in all metastatic colorectal cancers, more than 50% of tumors are expected to be resistant to EGFR-targeted antibodies (16).”
• Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. (2013, neutral): “Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
• Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 (2019, neutral): “Median tumor size, mm (range) 99 (11-408) 60 (10-307)”